[go: up one dir, main page]

PE20030282A1 - Anticuerpos de interleucina-1- beta - Google Patents

Anticuerpos de interleucina-1- beta

Info

Publication number
PE20030282A1
PE20030282A1 PE2002000654A PE2002000654A PE20030282A1 PE 20030282 A1 PE20030282 A1 PE 20030282A1 PE 2002000654 A PE2002000654 A PE 2002000654A PE 2002000654 A PE2002000654 A PE 2002000654A PE 20030282 A1 PE20030282 A1 PE 20030282A1
Authority
PE
Peru
Prior art keywords
seq
antibody
interleukin
refers
beta antibodies
Prior art date
Application number
PE2002000654A
Other languages
English (en)
Inventor
Stuart Willis Bright
Stuart Allen Kuhstoss
Naoya Tsurushita
Maximiliano J Vasquez
Audrey Yunhua Jia
Joseph Vincent Manetta
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20030282A1 publication Critical patent/PE20030282A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE REFIERE A UN ANTICUERPO QUE ESPECIFICAMENTE ENLAZA LA IL-1ß MADURA, CARACTERIZADO PORQUE EL ANTICUERPO ENLAZA EL MISMO EPITOPE EN LA IL-1ß HUMANA MADURA QUE EL ANTICUERPO MONOCLONAL DE RATON Mu007 O ANTICUERPO HUMANIZADO Hu007. EL ANTICUERPO COMPRENDE AL MENOS UNA REGION DETERMINANTE DE COMPLEMENTARIEDAD QUE TIENE UNA SECUENCIA SELECCIONADA DEL GRUPO QUE CONSISTE DE ID SEC No: 5, ID SEC No: 6, ID SEC No: 7, ID SEC No: 8, ID SEC No: 9, ID SEC No: 10 Y UNA REGION VARIABLE CON UNA CADENA LIGERA QUE TIENE LA SECUENC IA DE ID SEC No: 27, ID SEC No: 28. SE REFIERE TAMBIEN A ANTICUERPOS DE ALTA AFINIDAD QUE NEUTRALIZAN LA ACTIVIDAD DE LA INTERLEUCINA-1ß (IL-1ß) Y SE PUEDEN USAR PARA EL TRATAMIENTO DE ARTRITIS REUMATOIDE Y OSTEOARTRITIS
PE2002000654A 2001-07-26 2002-07-24 Anticuerpos de interleucina-1- beta PE20030282A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30797301P 2001-07-26 2001-07-26
US31227801P 2001-08-14 2001-08-14

Publications (1)

Publication Number Publication Date
PE20030282A1 true PE20030282A1 (es) 2003-03-25

Family

ID=26976031

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000654A PE20030282A1 (es) 2001-07-26 2002-07-24 Anticuerpos de interleucina-1- beta

Country Status (8)

Country Link
US (1) US20050075488A1 (es)
EP (1) EP1423432A4 (es)
JP (1) JP2004536605A (es)
AR (1) AR036189A1 (es)
AU (1) AU2002355249A1 (es)
PE (1) PE20030282A1 (es)
SV (1) SV2003001183A (es)
WO (1) WO2003010282A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1481010A2 (en) * 2002-02-28 2004-12-01 Eli Lilly And Company Anti-interleukin-1 beta analogs
ES2567198T3 (es) * 2003-01-24 2016-04-20 Applied Molecular Evolution, Inc. Antagonistas de la IL-1 beta humana
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
WO2006081139A2 (en) 2005-01-26 2006-08-03 Abgenix, Inc. Antibodies against interleukin-1 beta
SI2314623T1 (sl) 2005-06-21 2012-11-30 Xoma Technology Ltd IL beta vezavna protitelesa in njihovi fragmenti
EP1896072A4 (en) * 2005-06-24 2013-01-09 Univ Duke SYSTEM FOR DIRECT HEALTH MANAGEMENT BASED ON HEAT-CONTROLLED BIOPOLYMERS
WO2007050607A2 (en) * 2005-10-26 2007-05-03 Novartis Ag Novel use of il-1beta compounds
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
MX2009006709A (es) * 2006-12-20 2009-07-02 Xoma Technology Ltd Tratamiento de enfermedades relacionadas con il-1beta.
CA2839162A1 (en) * 2006-12-20 2008-06-26 Xoma Technology Ltd. Methods for the treatment of il-1-.beta. related diseases
WO2009086003A1 (en) * 2007-12-20 2009-07-09 Xoma Technology Ltd. Methods for the treatment of gout
JP5607613B2 (ja) * 2008-06-06 2014-10-15 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー 関節リウマチの治療のための方法
WO2010028273A1 (en) 2008-09-05 2010-03-11 Xoma Technology Ltd. Methods for improvement of beta cell function
CA2797846A1 (en) 2010-05-07 2011-11-10 Xoma Technology Ltd. Methods for the treatment of il-1.beta. related conditions
US20110307788A1 (en) * 2010-06-15 2011-12-15 Microsoft Corporation Role-based presentation views
JP6320300B2 (ja) 2011-12-19 2018-05-09 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー 座瘡を治療するための方法
US10436795B2 (en) * 2016-09-16 2019-10-08 Institute For Cancer Research Carbon-detected NMR for mapping binding sites in intrinsically disordered regions of a protein

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
EP0569687B1 (en) * 1984-05-18 2002-08-21 New England Medical Center Hospitals, Inc. Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins
US5484887A (en) * 1984-06-19 1996-01-16 Immunex Corporation Homogeneous interleukin 1
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4935343A (en) * 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
WO1995001997A1 (en) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
US20020155114A1 (en) * 1998-08-31 2002-10-24 James D. Marks Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
WO2000053794A2 (en) 1999-03-12 2000-09-14 Agritope, Inc. Trait-associated gene identification method

Also Published As

Publication number Publication date
US20050075488A1 (en) 2005-04-07
JP2004536605A (ja) 2004-12-09
EP1423432A2 (en) 2004-06-02
SV2003001183A (es) 2003-07-29
EP1423432A4 (en) 2006-01-11
WO2003010282A3 (en) 2004-02-12
WO2003010282A2 (en) 2003-02-06
AU2002355249A1 (en) 2003-02-17
AR036189A1 (es) 2004-08-18

Similar Documents

Publication Publication Date Title
PE20030282A1 (es) Anticuerpos de interleucina-1- beta
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
PE20001316A1 (es) Anticuerpo humanizado especifico para 4-1bb humano y composicion farmaceutica que lo contiene
SI2481753T1 (en) Anti-IL-17 antibodies
AR085874A2 (es) Un anticuerpo monoclonal o un fragmento del mismo que se une a un antigeno
UA92504C2 (en) Anti-myostatin monoclonal antibody
ES2653664T3 (es) Generación y caracterización de anticuerpos terapéuticos obtenidos mediante HuCal GOLD completamente humanos específicos de CD38 humano
NZ602780A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
DE60142614D1 (de) Inität
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
AR075790A2 (es) Anticuerpos anti -ngf humanos neutralizantes como inhibidores selectivos de la via de ngf (factor de crecimiento neural)
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
AR035119A1 (es) Anticuerpos humanos antagonistas anti-htnfsf13b
PE20061324A1 (es) Anticuerpos anti-il-6, composiciones, metodos y usos
CU23292B7 (es) Anticuerpos monoclonales humanos de ctla-4
CO6190543A2 (es) Anticuerpos anti-factor d humanizados
CY1113224T1 (el) Νεο αντισωμα αντι-ρlgf
ATE477273T1 (de) Humanisierte antikoerper gegen gamma-interferon
MY199530A (en) Anti-cd3epsilon antibodies
RU2012102323A (ru) Способ лечения ревматоидного артрита посредством лекарственного препарата на основе выделенного человеческого антитела или его антигенсвязывающего фрагмента
MXPA05007853A (es) Antagonistas de il-1 beta humana.
WO2010076400A8 (fr) Utilisation d'un anticorps anti-cd20 pour le traitement du lymphome intraoculaire primitif
DE69128543D1 (de) Monoklonale antikörper der maus
AR038700A1 (es) Anticuerpos monoclonales anti-tenascina humana
PE20232050A1 (es) Anticuerpos anti-cd19 y estructuras car-t

Legal Events

Date Code Title Description
FA Abandonment or withdrawal